<button id="eiezk"><video id="eiezk"></video></button>

產(chǎn)品名稱

PKI 587 - PF 05212384

產(chǎn)品貨號

Axon 1807 CAS [1197160-78-3] MF C32H41N9O4MW 615.73 Purity: 99% Moderately soluble in DMSO Description Highly potent PI3K/mTOR kinase inhibitor; PKI-587 inhibits PI3K-α, β, γ, δ isoforms and mTOR with IC50 of 0.4, 6.0, 5.4, 6.0 and 1.6 nM respectively. PKI-587 inhibits mTOR TOC1 kinase activity in human MDA-MB-361 cells assessed as surppression of 4EBP1 phosphorylation at <30 nM; PKI-587 inhibits Akt S473 phosphorylation in human MDA-MB-361 cells and Akt T308 phosphorylation in human MDA-MB-361 cells with IC50 of 8nM and 10 nM References Certificates Categories Extra info R Mallon et al. Antitumor efficacy of PKI-587, a highly potent dual PI3K/mTOR kinase inhibitor. Clin Cancer Res. 2011, 17(10), 3193-203.? ? R Gedaly et al. PKI-587 and Sorafenib Targeting PI3K/AKT/mTOR and Ras/Raf/MAPK Pathways Synergistically Inhibit HCC Cell Proliferation. J. Surg. Res. 2011, 1-7. ? AM Venkatesan?et al. Bis(morpholino-1,3,5-triazine) derivatives: Potent adenosine 5’-triphosphate competitive phosphatidylinositol-3-kinase/mammalian target of rapamycin inhibitors: Discovery of compound 26 (PKI-587) (...). J. Med. Chem. 2010, 53, 2636.? Certificate of Analysis Material Safety Data Sheet Cell Signaling & Oncology PI3K mTOR PI3K-Akt-mTOR EC 2.7.11.1 Pfizer Licensed Products Dual PI3K and mTOR inhibitor Chemical name 1-(4-(4-(dimethylamino)piperidine-1-carbonyl)phenyl)-3-(4-(4,6-dimorpholino-1,3,5-triazin-2-yl)phenyl)urea Source information Pfizer compound; Sold for research purposes under agreement from Pfizer Inc. Parent CAS No. [1197160-78-3] Order Size Unit Price Stock 5 mg €90.00 In Stock

產(chǎn)品價格

現(xiàn)貨詢價，電話：010-67529703

產(chǎn)品規(guī)格

產(chǎn)品品牌

axonmedchem

產(chǎn)品概述

產(chǎn)品詳情

PKI 587 - PF 05212384

Based on 12 reference(s) in Google Scholar 9 10 12

Axon 1807

CAS [1197160-78-3]

MF C32H41N9O4
MW 615.73

Purity: 99%
Moderately soluble in DMSO

PKI 587

Description

Highly potent PI3K/mTOR kinase inhibitor; PKI-587 inhibits PI3K-α, β, γ, δ isoforms and mTOR with IC50 of 0.4, 6.0, 5.4, 6.0 and 1.6 nM respectively. PKI-587 inhibits mTOR TOC1 kinase activity in human MDA-MB-361 cells assessed as surppression of 4EBP1 phosphorylation at <30 nM; PKI-587 inhibits Akt S473 phosphorylation in human MDA-MB-361 cells and Akt T308 phosphorylation in human MDA-MB-361 cells with IC50 of 8nM and 10 nM

R Mallon et al. Antitumor efficacy of PKI-587, a highly potent dual PI3K/mTOR kinase inhibitor. Clin Cancer Res. 2011, 17(10), 3193-203.?

R Gedaly et al. PKI-587 and Sorafenib Targeting PI3K/AKT/mTOR and Ras/Raf/MAPK Pathways Synergistically Inhibit HCC Cell Proliferation. J. Surg. Res. 2011, 1-7.

AM Venkatesan?et al. Bis(morpholino-1,3,5-triazine) derivatives: Potent adenosine 5’-triphosphate competitive phosphatidylinositol-3-kinase/mammalian target of rapamycin inhibitors: Discovery of compound 26 (PKI-587) (...). J. Med. Chem. 2010, 53, 2636.?

Certificate of Analysis
Material Safety Data Sheet

Cell Signaling & Oncology PI3K mTOR PI3K-Akt-mTOR EC 2.7.11.1 Pfizer Licensed Products

Dual PI3K and mTOR inhibitor

Chemical name

1-(4-(4-(dimethylamino)piperidine-1-carbonyl)phenyl)-3-(4-(4,6-dimorpholino-1,3,5-triazin-2-yl)phenyl)urea

Source information

Pfizer compound; Sold for research purposes under agreement from Pfizer Inc.

Parent CAS No.

[1197160-78-3]

產(chǎn)品資料

<button id="eiezk"><video id="eiezk"></video></button>